Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Metric	Value
Current Market Cap	$3.00B
Last Price	$61.76
52-Week High	$53.56
52-Week Low	$5.49

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORKA	$61.76	+1.91%	1.21M
3
4
5

Oruka Therapeutics Inc. (ORKA) Market Capitalization

Market Cap Data

Get Oruka Therapeutics Inc. Data in Excel

More ORKA Financial Data